Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy
Jonathan Chou, David A. Quigley, Troy M. Robinson, et al.
Cancer Discovery (2020) Vol. 10, Iss. 3, pp. 351-370
Open Access | Times Cited: 234

Showing 1-25 of 234 citing articles:

Mechanisms of lncRNA biogenesis as revealed by nascent transcriptomics
Takayuki Nojima, Nicholas Proudfoot
Nature Reviews Molecular Cell Biology (2022) Vol. 23, Iss. 6, pp. 389-406
Closed Access | Times Cited: 292
The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer
Stephin J. Vervoort, Sarah A. Welsh, Jennifer R. Devlin, et al.
Cell (2021) Vol. 184, Iss. 12, pp. 3143-3162.e32
Open Access | Times Cited: 166
Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications
Qian Zhong, Xina Xiao, Yijie Qiu, et al.
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 117
Applications of protein ubiquitylation and deubiquitylation in drug discovery
Yilin Chen, Haoan Xue, Jianping Jin
Journal of Biological Chemistry (2024) Vol. 300, Iss. 5, pp. 107264-107264
Open Access | Times Cited: 17
Cyclin-dependent protein kinases and cell cycle regulation in biology and disease
Ilenia Pellarin, Alessandra Dall’Acqua, Andrea Favero, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 9
Design, synthesis and biological evaluation of dual CDK9/PARP inhibitors for the treatment of cancer
Jindi Huang, Ya He, Sumeng Chen, et al.
European Journal of Medicinal Chemistry (2025) Vol. 287, pp. 117367-117367
Closed Access | Times Cited: 2
Targeting transcription cycles in cancer
Stephin J. Vervoort, Jennifer R. Devlin, Nicholas Kwiatkowski, et al.
Nature reviews. Cancer (2021) Vol. 22, Iss. 1, pp. 5-24
Closed Access | Times Cited: 99
Targeting CDK9 for Anti-Cancer Therapeutics
Ranadip Mandal, Sven Becker, Klaus Strebhardt
Cancers (2021) Vol. 13, Iss. 9, pp. 2181-2181
Open Access | Times Cited: 83
Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update
Tizhi Wu, Zhen Qin, Yucheng Tian, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 22, pp. 13228-13257
Closed Access | Times Cited: 78
Targeting CDK12 for Cancer Therapy: Function, Mechanism, and Drug Discovery
Hui Liu, Kangdong Liu, Zigang Dong
Cancer Research (2020) Vol. 81, Iss. 1, pp. 18-26
Open Access | Times Cited: 75
Selective inhibition of CDK7 reveals high-confidence targets and new models for TFIIH function in transcription
Jenna K. Rimel, Zachary C. Poss, Benjamin Erickson, et al.
Genes & Development (2020) Vol. 34, Iss. 21-22, pp. 1452-1473
Open Access | Times Cited: 72
Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts
Zhouling Xie, Shuzeng Hou, Xiaoxiao Yang, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 9, pp. 6356-6389
Closed Access | Times Cited: 46
Transcription Elongation Machinery Is a Druggable Dependency and Potentiates Immunotherapy in Glioblastoma Stem Cells
Zhixin Qiu, Linjie Zhao, Jia Shen, et al.
Cancer Discovery (2022) Vol. 12, Iss. 2, pp. 502-521
Open Access | Times Cited: 43
Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13
Jianzhang Yang, Yu Chang, Jean C. Tien, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 16, pp. 11066-11083
Open Access | Times Cited: 43
From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy
Zhenfeng Shi, Lei Tian, Taotao Qiang, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 9, pp. 6390-6418
Closed Access | Times Cited: 40
CDK13 promotes lipid deposition and prostate cancer progression by stimulating NSUN5-mediated m5C modification of ACC1 mRNA
Yong Zhang, Xiaonan Chen, Hong Zhang, et al.
Cell Death and Differentiation (2023) Vol. 30, Iss. 12, pp. 2462-2476
Closed Access | Times Cited: 30
Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids
Eleonora Cesari, Alessandra Ciucci, Marco Pieraccioli, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 25
Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer
Jun Ma, Jack Junjie Chan, Ching Han Toh, et al.
npj Breast Cancer (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 25
Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments
Lanshu Xiao, Yi Liu, Hui Chen, et al.
Cancer Biology & Therapy (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 24
Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications
Yuming Zhang, Lianhai Shan, Wentao Tang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 7, pp. 5185-5215
Closed Access | Times Cited: 14
Beta-elemene: A phytochemical with promise as a drug candidate for tumor therapy and adjuvant tumor therapy
Yewen Feng, Qingwen An, Zhengqi Zhao, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 172, pp. 116266-116266
Open Access | Times Cited: 13
Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Charles B. Nguyen, Melissa A. Reimers, Chamila Perera, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 15, pp. 3200-3210
Closed Access | Times Cited: 8
CDK12: A Potent Target and Biomarker for Human Cancer Therapy
Shujing Liang, Lifang Hu, Zixiang Wu, et al.
Cells (2020) Vol. 9, Iss. 6, pp. 1483-1483
Open Access | Times Cited: 58
Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer
Kyu Sic You, Yong Weon Yi, Jeonghee Cho, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 6, pp. 589-589
Open Access | Times Cited: 48
Molecular mechanisms and therapeutic implications of dihydromyricetin in liver disease
Jingnan Chen, Xitong Wang, Tian Xia, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 142, pp. 111927-111927
Open Access | Times Cited: 43
Page 1 - Next Page

Scroll to top